Preferred Label : Anti-Claudin18.2/Anti-CD3 Bispecific Antibody AZD5863;
NCIt synonyms : CLDN18.2xCD3 Bispecific Antibody AZD5863; Anti-CLDN18.2/Anti-CD3 Bispecific Antibody AZD5863; T-cell Engager AZD5863; CLDN18.2 x CD3 Bispecific Antibody AZD5863; TCE AZD5863;
NCIt definition : An affinity-optimized T-cell engaging (TCE) and human bispecific antibody directed
against the tumor-associated antigen (TAA) Claudin18.2 (CLDN18.2; A2 isoform of claudin-18)
and the human T-cell surface antigen CD3, with potential immunostimulatory and antineoplastic
activities. Upon administration, anti-CLDN18.2/anti-CD3 bispecific antibody AZD5863
simultaneously targets and binds to both CLDN18.2-expressing tumor cells, with bivalent
high affinity binding, and CD3-expressing T-cells, with monovalent low affinity binding.
This crosslinks CLDN18.2-expressing tumor cells and cytotoxic T-lymphocytes (CTLs)
and results in the activation and proliferation of T-cells. This causes a CTL-mediated
cell lysis of CLDN18.2-expressing tumor cells. Additionally, AZD5863 induces bystander
killing of CLDN18.2-negative tumor cells. CLDN18.2, a tight junction protein and stomach-specific
isoform of claudin-18, is expressed on a variety of tumor cells. Its expression in
healthy tissues is strictly confined to short-lived differentiated epithelial cells
of the gastric mucosa. The bivalent high-affinity binding to CLDN18.2 and monovalent
low-affinity binding to CD3 of AZD5863 may reduce toxicities while optimizing specific
anti-tumor activity.;
Molecule name : AZD-5863; HBM 7022; HBM-7022; AZD 5863;
NCI Metathesaurus CUI : CL1928975;
Origin ID : C206446;
chemical_or_drug_has_mechanism_of_action
- concept_is_in_subset
- has_target
